Maxigen Biotech Inc. (TPE:1783)

Market Cap	3.57B -10.3%
Revenue (ttm)	825.25M +12.9%
Net Income	271.02M +29.8%
EPS	3.00 +29.5%
Shares Out	89.68M
PE Ratio	13.28
Forward PE	n/a
Dividend	2.00 (4.99%)
Ex-Dividend Date	Sep 1, 2026

Volume	54,256
Open	40.10
Previous Close	39.85
Day's Range	39.55 - 40.20
52-Week Range	37.80 - 48.85
Beta	0.17
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 4, 2026

About Maxigen Biotech

Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, dental, surgical, orthopedics, electronic instructions for use, and medical aesthetics, as well as engages in collagen purification activities. It also ...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1998
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1783

Financial Performance

In 2025, Maxigen Biotech's revenue was 811.56 million, an increase of 19.23% compared to the previous year's 680.65 million. Earnings were 265.31 million, an increase of 39.52%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 30, 2026

Data Sources Report a data error